Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93676705 | 9367670 | 5 | F | 20120424 | 20141003 | 20130625 | 20160906 | EXP | PHHY2013JP041335 | NOVARTIS | 54.83 | YR | F | Y | 0.00000 | 20160906 | MD | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 93676705 | 9367670 | 1 | PS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | 840 | MG | 22334 | 10 | MG | TABLET | QD | ||||
| 93676705 | 9367670 | 2 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 5 MG, QD | 840 | MG | 22334 | 5 | MG | TABLET | QD | ||||
| 93676705 | 9367670 | 3 | SS | AFINITOR | EVEROLIMUS | 1 | Oral | 10 MG, QD | 840 | MG | 22334 | 10 | MG | TABLET | QD | ||||
| 93676705 | 9367670 | 4 | C | SANDOSTATIN LAR DEPOT | OCTREOTIDE ACETATE | 1 | Intramuscular | U | 0 | ||||||||||
| 93676705 | 9367670 | 5 | C | BLOPRESS | CANDESARTAN CILEXETIL | 1 | Oral | 16 MG, UNK | U | 0 | 16 | MG | |||||||
| 93676705 | 9367670 | 6 | C | NORVASC | AMLODIPINE BESYLATE | 1 | Oral | 10 MG, UNK | U | 0 | 10 | MG | |||||||
| 93676705 | 9367670 | 7 | C | ALOSITOL | ALLOPURINOL | 1 | Oral | 100 MG | U | 0 | 100 | MG | |||||||
| 93676705 | 9367670 | 8 | C | BEZATOL SR | BEZAFIBRATE | 1 | Oral | 400 MG, UNK | Y | 0 | 400 | MG | |||||||
| 93676705 | 9367670 | 9 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 10 MG, UNK | U | 0 | 10 | MG | |||||||
| 93676705 | 9367670 | 10 | C | LIPITOR | ATORVASTATIN CALCIUM | 1 | Oral | 20 MG, UNK | U | 0 | 20 | MG | |||||||
| 93676705 | 9367670 | 11 | C | LENDORMIN | BROTIZOLAM | 1 | Oral | 0.25 MG, UNK | U | 0 | .25 | MG |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 93676705 | 9367670 | 1 | Pancreatic neuroendocrine tumour |
| 93676705 | 9367670 | 4 | Pancreatic neuroendocrine tumour |
| 93676705 | 9367670 | 5 | Product used for unknown indication |
| 93676705 | 9367670 | 6 | Product used for unknown indication |
| 93676705 | 9367670 | 7 | Product used for unknown indication |
| 93676705 | 9367670 | 8 | Prophylaxis |
| 93676705 | 9367670 | 9 | Prophylaxis |
| 93676705 | 9367670 | 11 | Prophylaxis |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 93676705 | 9367670 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 93676705 | 9367670 | Alanine aminotransferase increased | |
| 93676705 | 9367670 | Aspartate aminotransferase increased | |
| 93676705 | 9367670 | Decreased appetite | |
| 93676705 | 9367670 | Dysgeusia | |
| 93676705 | 9367670 | Epistaxis | |
| 93676705 | 9367670 | Gamma-glutamyltransferase increased | |
| 93676705 | 9367670 | Hyperuricaemia | |
| 93676705 | 9367670 | Stomatitis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 93676705 | 9367670 | 1 | 20120201 | 20120814 | 0 | |
| 93676705 | 9367670 | 2 | 20120828 | 20120903 | 0 | |
| 93676705 | 9367670 | 3 | 20120904 | 0 | ||
| 93676705 | 9367670 | 8 | 20120214 | 20121015 | 0 | |
| 93676705 | 9367670 | 9 | 20120410 | 0 | ||
| 93676705 | 9367670 | 11 | 20120612 | 0 |